Bradley Foster & Sargent Inc. CT Has $1.38 Million Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Bradley Foster & Sargent Inc. CT trimmed its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,412 shares of the financial services provider’s stock after selling 250 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in iShares Biotechnology ETF were worth $1,377,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Huntington National Bank raised its position in shares of iShares Biotechnology ETF by 17.9% in the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after buying an additional 160 shares in the last quarter. National Bank of Canada FI raised its position in shares of iShares Biotechnology ETF by 5.9% in the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after buying an additional 229 shares in the last quarter. Avior Wealth Management LLC raised its position in iShares Biotechnology ETF by 438.2% during the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after purchasing an additional 2,629 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after purchasing an additional 164,000 shares in the last quarter. Finally, Main Management ETF Advisors LLC raised its position in iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after purchasing an additional 14,535 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $138.91 on Friday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The firm has a 50 day simple moving average of $135.61 and a two-hundred day simple moving average of $140.77.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.